US8333972B2 - Unconventional antigen translated by a novel internal ribosome entry site elicits antitumor humoral immune reactions - Google Patents
Unconventional antigen translated by a novel internal ribosome entry site elicits antitumor humoral immune reactions Download PDFInfo
- Publication number
- US8333972B2 US8333972B2 US12/377,444 US37744407A US8333972B2 US 8333972 B2 US8333972 B2 US 8333972B2 US 37744407 A US37744407 A US 37744407A US 8333972 B2 US8333972 B2 US 8333972B2
- Authority
- US
- United States
- Prior art keywords
- mpd6
- ires
- ifn
- antigen
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related, expires
Links
- 239000000427 antigen Substances 0.000 title abstract description 106
- 108091007433 antigens Proteins 0.000 title abstract description 93
- 102000036639 antigens Human genes 0.000 title abstract description 92
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 title abstract description 58
- 230000000259 anti-tumor effect Effects 0.000 title description 3
- 230000008105 immune reaction Effects 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 71
- 239000012634 fragment Substances 0.000 claims description 42
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 41
- 229920001184 polypeptide Polymers 0.000 claims description 34
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 18
- 230000002163 immunogen Effects 0.000 claims description 17
- 101001054841 Homo sapiens Leucine zipper protein 6 Proteins 0.000 abstract description 174
- 102100026913 Leucine zipper protein 6 Human genes 0.000 abstract description 167
- 102000006992 Interferon-alpha Human genes 0.000 abstract description 116
- 108010047761 Interferon-alpha Proteins 0.000 abstract description 116
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 abstract description 110
- 230000000638 stimulation Effects 0.000 abstract description 48
- 238000013519 translation Methods 0.000 abstract description 48
- 108700026244 Open Reading Frames Proteins 0.000 abstract description 37
- 230000001404 mediated effect Effects 0.000 abstract description 30
- 230000004044 response Effects 0.000 abstract description 29
- 102000006392 myotrophin Human genes 0.000 abstract description 26
- 108010058605 myotrophin Proteins 0.000 abstract description 26
- 108020004999 messenger RNA Proteins 0.000 abstract description 24
- 230000007246 mechanism Effects 0.000 abstract description 23
- 238000013518 transcription Methods 0.000 abstract description 19
- 230000035897 transcription Effects 0.000 abstract description 19
- 108020005345 3' Untranslated Regions Proteins 0.000 abstract description 17
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 abstract description 16
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 abstract description 16
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 abstract description 16
- 238000011144 upstream manufacturing Methods 0.000 abstract description 16
- 230000005875 antibody response Effects 0.000 abstract description 12
- 230000005975 antitumor immune response Effects 0.000 abstract description 11
- 238000009169 immunotherapy Methods 0.000 abstract description 9
- 208000014767 Myeloproliferative disease Diseases 0.000 abstract description 8
- 108091036066 Three prime untranslated region Proteins 0.000 abstract description 7
- 206010060862 Prostate cancer Diseases 0.000 abstract description 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract description 6
- 210000004027 cell Anatomy 0.000 description 93
- 206010028980 Neoplasm Diseases 0.000 description 70
- 230000014509 gene expression Effects 0.000 description 64
- 108090000623 proteins and genes Proteins 0.000 description 63
- 238000000034 method Methods 0.000 description 56
- 239000013598 vector Substances 0.000 description 53
- 102000004169 proteins and genes Human genes 0.000 description 49
- 230000014616 translation Effects 0.000 description 49
- 150000007523 nucleic acids Chemical group 0.000 description 38
- 239000000203 mixture Substances 0.000 description 32
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 31
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 30
- 108010021843 fluorescent protein 583 Proteins 0.000 description 29
- 102000039446 nucleic acids Human genes 0.000 description 27
- 108020004707 nucleic acids Proteins 0.000 description 27
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 26
- 150000001413 amino acids Chemical group 0.000 description 26
- 208000017733 acquired polycythemia vera Diseases 0.000 description 25
- 208000037244 polycythemia vera Diseases 0.000 description 25
- 239000000523 sample Substances 0.000 description 24
- 230000028993 immune response Effects 0.000 description 22
- 108700008625 Reporter Genes Proteins 0.000 description 21
- 201000010099 disease Diseases 0.000 description 19
- 239000002299 complementary DNA Substances 0.000 description 18
- 238000002560 therapeutic procedure Methods 0.000 description 18
- 241000282414 Homo sapiens Species 0.000 description 15
- 201000011510 cancer Diseases 0.000 description 15
- 238000011282 treatment Methods 0.000 description 15
- 208000023275 Autoimmune disease Diseases 0.000 description 14
- 108091028043 Nucleic acid sequence Proteins 0.000 description 14
- 238000004458 analytical method Methods 0.000 description 14
- 239000003795 chemical substances by application Substances 0.000 description 14
- 206010061218 Inflammation Diseases 0.000 description 13
- 208000036142 Viral infection Diseases 0.000 description 13
- 230000004054 inflammatory process Effects 0.000 description 13
- 230000009385 viral infection Effects 0.000 description 13
- 108020004414 DNA Proteins 0.000 description 12
- 229940024606 amino acid Drugs 0.000 description 12
- 238000001514 detection method Methods 0.000 description 12
- 208000035475 disorder Diseases 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 238000000746 purification Methods 0.000 description 11
- 229960005486 vaccine Drugs 0.000 description 11
- 108091081024 Start codon Proteins 0.000 description 10
- 230000000890 antigenic effect Effects 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 238000000338 in vitro Methods 0.000 description 10
- 210000004881 tumor cell Anatomy 0.000 description 10
- 102000007469 Actins Human genes 0.000 description 9
- 108010085238 Actins Proteins 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 9
- 230000001580 bacterial effect Effects 0.000 description 9
- 210000003527 eukaryotic cell Anatomy 0.000 description 9
- 238000009739 binding Methods 0.000 description 8
- 238000012217 deletion Methods 0.000 description 8
- 230000037430 deletion Effects 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 210000001550 testis Anatomy 0.000 description 8
- 230000003827 upregulation Effects 0.000 description 8
- 230000000692 anti-sense effect Effects 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 230000027455 binding Effects 0.000 description 7
- 230000001419 dependent effect Effects 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 230000001939 inductive effect Effects 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 102000040430 polynucleotide Human genes 0.000 description 7
- 108091033319 polynucleotide Proteins 0.000 description 7
- 239000002157 polynucleotide Substances 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 7
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 6
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 6
- 238000000636 Northern blotting Methods 0.000 description 6
- 210000004899 c-terminal region Anatomy 0.000 description 6
- 238000010367 cloning Methods 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000003757 reverse transcription PCR Methods 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 208000011691 Burkitt lymphomas Diseases 0.000 description 5
- 102100035549 Eukaryotic translation initiation factor 2 subunit 1 Human genes 0.000 description 5
- 101710151743 Eukaryotic translation initiation factor 2 subunit 1 Proteins 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 101001057508 Homo sapiens Ubiquitin-like protein ISG15 Proteins 0.000 description 5
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 102100027266 Ubiquitin-like protein ISG15 Human genes 0.000 description 5
- 210000001124 body fluid Anatomy 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 238000009396 hybridization Methods 0.000 description 5
- 230000005847 immunogenicity Effects 0.000 description 5
- 208000025113 myeloid leukemia Diseases 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 238000004393 prognosis Methods 0.000 description 5
- 210000001236 prokaryotic cell Anatomy 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 4
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 4
- 238000009007 Diagnostic Kit Methods 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000005720 Glutathione transferase Human genes 0.000 description 4
- 108010070675 Glutathione transferase Proteins 0.000 description 4
- 108091092195 Intron Proteins 0.000 description 4
- 108060001084 Luciferase Proteins 0.000 description 4
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 description 4
- 239000004793 Polystyrene Substances 0.000 description 4
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 239000010839 body fluid Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000011132 hemopoiesis Effects 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 229920002223 polystyrene Polymers 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- -1 strips Substances 0.000 description 4
- 230000002103 transcriptional effect Effects 0.000 description 4
- 241001515965 unidentified phage Species 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- 108700028369 Alleles Proteins 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 241000701022 Cytomegalovirus Species 0.000 description 3
- 241000710188 Encephalomyocarditis virus Species 0.000 description 3
- 239000004366 Glucose oxidase Substances 0.000 description 3
- 108010015776 Glucose oxidase Proteins 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 108010038807 Oligopeptides Proteins 0.000 description 3
- 102000015636 Oligopeptides Human genes 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 230000001276 controlling effect Effects 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 229940116332 glucose oxidase Drugs 0.000 description 3
- 235000019420 glucose oxidase Nutrition 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000003053 immunization Effects 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 229960000310 isoleucine Drugs 0.000 description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 229940124606 potential therapeutic agent Drugs 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 108020001580 protein domains Proteins 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- OBYNJKLOYWCXEP-UHFFFAOYSA-N 2-[3-(dimethylamino)-6-dimethylazaniumylidenexanthen-9-yl]-4-isothiocyanatobenzoate Chemical compound C=12C=CC(=[N+](C)C)C=C2OC2=CC(N(C)C)=CC=C2C=1C1=CC(N=C=S)=CC=C1C([O-])=O OBYNJKLOYWCXEP-UHFFFAOYSA-N 0.000 description 2
- 206010001197 Adenocarcinoma of the cervix Diseases 0.000 description 2
- 208000034246 Adenocarcinoma of the cervix uteri Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 102100037024 E3 ubiquitin-protein ligase XIAP Human genes 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 108700039887 Essential Genes Proteins 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 2
- 108010057466 NF-kappa B Proteins 0.000 description 2
- 102000003945 NF-kappa B Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 241000714474 Rous sarcoma virus Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000005867 T cell response Effects 0.000 description 2
- 101710137500 T7 RNA polymerase Proteins 0.000 description 2
- 108091023045 Untranslated Region Proteins 0.000 description 2
- 210000001766 X chromosome Anatomy 0.000 description 2
- 108700031544 X-Linked Inhibitor of Apoptosis Proteins 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000030741 antigen processing and presentation Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 201000006662 cervical adenocarcinoma Diseases 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 230000002559 cytogenic effect Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 238000001215 fluorescent labelling Methods 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- 230000005251 gamma ray Effects 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 102000034356 gene-regulatory proteins Human genes 0.000 description 2
- 108091006104 gene-regulatory proteins Proteins 0.000 description 2
- 230000028996 humoral immune response Effects 0.000 description 2
- 238000010185 immunofluorescence analysis Methods 0.000 description 2
- 230000036046 immunoreaction Effects 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 239000004800 polyvinyl chloride Substances 0.000 description 2
- 229920000915 polyvinyl chloride Polymers 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 201000006845 reticulosarcoma Diseases 0.000 description 2
- 208000029922 reticulum cell sarcoma Diseases 0.000 description 2
- 210000003705 ribosome Anatomy 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 241000701447 unidentified baculovirus Species 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 206010046766 uterine cancer Diseases 0.000 description 2
- 208000012991 uterine carcinoma Diseases 0.000 description 2
- 210000003501 vero cell Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 description 1
- OGHAROSJZRTIOK-KQYNXXCUSA-N 2-amino-9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-methylpurin-9-ium-6-olate Chemical compound C12=NC(N)=NC([O-])=C2N(C)C=[N+]1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OGHAROSJZRTIOK-KQYNXXCUSA-N 0.000 description 1
- 101000621943 Acholeplasma phage L2 Probable integrase/recombinase Proteins 0.000 description 1
- 101000768957 Acholeplasma phage L2 Uncharacterized 37.2 kDa protein Proteins 0.000 description 1
- 101000823746 Acidianus ambivalens Uncharacterized 17.7 kDa protein in bps2 3'region Proteins 0.000 description 1
- 101000916369 Acidianus ambivalens Uncharacterized protein in sor 5'region Proteins 0.000 description 1
- 101000769342 Acinetobacter guillouiae Uncharacterized protein in rpoN-murA intergenic region Proteins 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- 101000823696 Actinobacillus pleuropneumoniae Uncharacterized glycosyltransferase in aroQ 3'region Proteins 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 101000786513 Agrobacterium tumefaciens (strain 15955) Uncharacterized protein outside the virF region Proteins 0.000 description 1
- 101000618005 Alkalihalobacillus pseudofirmus (strain ATCC BAA-2126 / JCM 17055 / OF4) Uncharacterized protein BpOF4_00885 Proteins 0.000 description 1
- 101000618348 Allochromatium vinosum (strain ATCC 17899 / DSM 180 / NBRC 103801 / NCIMB 10441 / D) Uncharacterized protein Alvin_0065 Proteins 0.000 description 1
- 102100020724 Ankyrin repeat, SAM and basic leucine zipper domain-containing protein 1 Human genes 0.000 description 1
- 101000781117 Autographa californica nuclear polyhedrosis virus Uncharacterized 12.4 kDa protein in CTL-LEF2 intergenic region Proteins 0.000 description 1
- 101000967489 Azorhizobium caulinodans (strain ATCC 43989 / DSM 5975 / JCM 20966 / LMG 6465 / NBRC 14845 / NCIMB 13405 / ORS 571) Uncharacterized protein AZC_3924 Proteins 0.000 description 1
- 101000708323 Azospirillum brasilense Uncharacterized 28.8 kDa protein in nifR3-like 5'region Proteins 0.000 description 1
- 101000770311 Azotobacter chroococcum mcd 1 Uncharacterized 19.8 kDa protein in nifW 5'region Proteins 0.000 description 1
- 101000823761 Bacillus licheniformis Uncharacterized 9.4 kDa protein in flaL 3'region Proteins 0.000 description 1
- 101000819719 Bacillus methanolicus Uncharacterized N-acetyltransferase in lysA 3'region Proteins 0.000 description 1
- 101000789586 Bacillus subtilis (strain 168) UPF0702 transmembrane protein YkjA Proteins 0.000 description 1
- 101000748761 Bacillus subtilis (strain 168) Uncharacterized MFS-type transporter YcxA Proteins 0.000 description 1
- 101000792624 Bacillus subtilis (strain 168) Uncharacterized protein YbxH Proteins 0.000 description 1
- 101000790792 Bacillus subtilis (strain 168) Uncharacterized protein YckC Proteins 0.000 description 1
- 101000765620 Bacillus subtilis (strain 168) Uncharacterized protein YlxP Proteins 0.000 description 1
- 101000819705 Bacillus subtilis (strain 168) Uncharacterized protein YlxR Proteins 0.000 description 1
- 101000916134 Bacillus subtilis (strain 168) Uncharacterized protein YqxJ Proteins 0.000 description 1
- 101000948218 Bacillus subtilis (strain 168) Uncharacterized protein YtxJ Proteins 0.000 description 1
- 101000718627 Bacillus thuringiensis subsp. kurstaki Putative RNA polymerase sigma-G factor Proteins 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 101000641200 Bombyx mori densovirus Putative non-structural protein Proteins 0.000 description 1
- 101000754349 Bordetella pertussis (strain Tohama I / ATCC BAA-589 / NCTC 13251) UPF0065 protein BP0148 Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 101800001415 Bri23 peptide Proteins 0.000 description 1
- 102400000107 C-terminal peptide Human genes 0.000 description 1
- 101800000655 C-terminal peptide Proteins 0.000 description 1
- 101100156752 Caenorhabditis elegans cwn-1 gene Proteins 0.000 description 1
- 101000827633 Caldicellulosiruptor sp. (strain Rt8B.4) Uncharacterized 23.9 kDa protein in xynA 3'region Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 101000947628 Claviceps purpurea Uncharacterized 11.8 kDa protein Proteins 0.000 description 1
- 101000947633 Claviceps purpurea Uncharacterized 13.8 kDa protein Proteins 0.000 description 1
- 101000686796 Clostridium perfringens Replication protein Proteins 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 241000701832 Enterobacteria phage T3 Species 0.000 description 1
- 101000948901 Enterobacteria phage T4 Uncharacterized 16.0 kDa protein in segB-ipI intergenic region Proteins 0.000 description 1
- 101000805958 Equine herpesvirus 4 (strain 1942) Virion protein US10 homolog Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 description 1
- 241001131785 Escherichia coli HB101 Species 0.000 description 1
- 101000790442 Escherichia coli Insertion element IS2 uncharacterized 11.1 kDa protein Proteins 0.000 description 1
- 101000788129 Escherichia coli Uncharacterized protein in sul1 3'region Proteins 0.000 description 1
- 101000788370 Escherichia phage P2 Uncharacterized 12.9 kDa protein in GpA 3'region Proteins 0.000 description 1
- 101000788354 Escherichia phage P2 Uncharacterized 8.2 kDa protein in gpA 5'region Proteins 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- 101000770304 Frankia alni UPF0460 protein in nifX-nifW intergenic region Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 101000797344 Geobacillus stearothermophilus Putative tRNA (cytidine(34)-2'-O)-methyltransferase Proteins 0.000 description 1
- 101000748410 Geobacillus stearothermophilus Uncharacterized protein in fumA 3'region Proteins 0.000 description 1
- 101000787096 Geobacillus stearothermophilus Uncharacterized protein in gldA 3'region Proteins 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
- 102100036242 HLA class II histocompatibility antigen, DQ alpha 2 chain Human genes 0.000 description 1
- 102000018932 HSP70 Heat-Shock Proteins Human genes 0.000 description 1
- 108010027992 HSP70 Heat-Shock Proteins Proteins 0.000 description 1
- 241000606768 Haemophilus influenzae Species 0.000 description 1
- 101000772675 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) UPF0438 protein HI_0847 Proteins 0.000 description 1
- 101000631019 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) Uncharacterized protein HI_0350 Proteins 0.000 description 1
- 101000976889 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 19.2 kDa protein in cox-rep intergenic region Proteins 0.000 description 1
- 101000768938 Haemophilus phage HP1 (strain HP1c1) Uncharacterized 8.9 kDa protein in int-C1 intergenic region Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 101000785414 Homo sapiens Ankyrin repeat, SAM and basic leucine zipper domain-containing protein 1 Proteins 0.000 description 1
- 101000930801 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 2 chain Proteins 0.000 description 1
- 101001109282 Homo sapiens NudC domain-containing protein 1 Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 102100022297 Integrin alpha-X Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000000646 Interleukin-3 Human genes 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 101000782488 Junonia coenia densovirus (isolate pBRJ/1990) Putative non-structural protein NS2 Proteins 0.000 description 1
- 102100040445 Keratin, type I cytoskeletal 14 Human genes 0.000 description 1
- 108010066321 Keratin-14 Proteins 0.000 description 1
- 102100037691 Kinesin-like protein KIF20B Human genes 0.000 description 1
- 108050007394 Kinesin-like protein KIF20B Proteins 0.000 description 1
- 101000827627 Klebsiella pneumoniae Putative low molecular weight protein-tyrosine-phosphatase Proteins 0.000 description 1
- 101000811523 Klebsiella pneumoniae Uncharacterized 55.8 kDa protein in cps region Proteins 0.000 description 1
- 101000818409 Lactococcus lactis subsp. lactis Uncharacterized HTH-type transcriptional regulator in lacX 3'region Proteins 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 101000878851 Leptolyngbya boryana Putative Fe(2+) transport protein A Proteins 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- 102000043129 MHC class I family Human genes 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101000758828 Methanosarcina barkeri (strain Fusaro / DSM 804) Uncharacterized protein Mbar_A1602 Proteins 0.000 description 1
- 101001122401 Middle East respiratory syndrome-related coronavirus (isolate United Kingdom/H123990006/2012) Non-structural protein ORF3 Proteins 0.000 description 1
- 101001130841 Middle East respiratory syndrome-related coronavirus (isolate United Kingdom/H123990006/2012) Non-structural protein ORF5 Proteins 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 101001055788 Mycolicibacterium smegmatis (strain ATCC 700084 / mc(2)155) Pentapeptide repeat protein MfpA Proteins 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 102100022475 NudC domain-containing protein 1 Human genes 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 101000740670 Orgyia pseudotsugata multicapsid polyhedrosis virus Protein C42 Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108091093037 Peptide nucleic acid Chemical group 0.000 description 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 101000769182 Photorhabdus luminescens Uncharacterized protein in pnp 3'region Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 208000009052 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 101000961392 Pseudescherichia vulneris Uncharacterized 29.9 kDa protein in crtE 3'region Proteins 0.000 description 1
- 101000731030 Pseudomonas oleovorans Poly(3-hydroxyalkanoate) polymerase 2 Proteins 0.000 description 1
- 101001065485 Pseudomonas putida Probable fatty acid methyltransferase Proteins 0.000 description 1
- 102000013009 Pyruvate Kinase Human genes 0.000 description 1
- 108020005115 Pyruvate Kinase Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 108010052090 Renilla Luciferases Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 101000711023 Rhizobium leguminosarum bv. trifolii Uncharacterized protein in tfuA 3'region Proteins 0.000 description 1
- 101000974028 Rhizobium leguminosarum bv. viciae (strain 3841) Putative cystathionine beta-lyase Proteins 0.000 description 1
- 101000756519 Rhodobacter capsulatus (strain ATCC BAA-309 / NBRC 16581 / SB1003) Uncharacterized protein RCAP_rcc00048 Proteins 0.000 description 1
- 101000948219 Rhodococcus erythropolis Uncharacterized 11.5 kDa protein in thcD 3'region Proteins 0.000 description 1
- 101000948156 Rhodococcus erythropolis Uncharacterized 47.3 kDa protein in thcA 5'region Proteins 0.000 description 1
- 101000917565 Rhodococcus fascians Uncharacterized 33.6 kDa protein in fasciation locus Proteins 0.000 description 1
- 102100040756 Rhodopsin Human genes 0.000 description 1
- 108090000820 Rhodopsin Proteins 0.000 description 1
- 101000790284 Saimiriine herpesvirus 2 (strain 488) Uncharacterized 9.5 kDa protein in DHFR 3'region Proteins 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 101000936719 Streptococcus gordonii Accessory Sec system protein Asp3 Proteins 0.000 description 1
- 101000936711 Streptococcus gordonii Accessory secretory protein Asp4 Proteins 0.000 description 1
- 101000929863 Streptomyces cinnamonensis Monensin polyketide synthase putative ketoacyl reductase Proteins 0.000 description 1
- 101000788499 Streptomyces coelicolor Uncharacterized oxidoreductase in mprA 5'region Proteins 0.000 description 1
- 101000788468 Streptomyces coelicolor Uncharacterized protein in mprR 3'region Proteins 0.000 description 1
- 101001102841 Streptomyces griseus Purine nucleoside phosphorylase ORF3 Proteins 0.000 description 1
- 101000708557 Streptomyces lincolnensis Uncharacterized 17.2 kDa protein in melC2-rnhH intergenic region Proteins 0.000 description 1
- 101000845085 Streptomyces violaceoruber Granaticin polyketide synthase putative ketoacyl reductase 1 Proteins 0.000 description 1
- 208000029052 T-cell acute lymphoblastic leukemia Diseases 0.000 description 1
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 101000649826 Thermotoga neapolitana Putative anti-sigma factor antagonist TM1081 homolog Proteins 0.000 description 1
- 101000711771 Thiocystis violacea Uncharacterized 76.5 kDa protein in phbC 3'region Proteins 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 1
- 101150007199 UTR5 gene Proteins 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 101000711318 Vibrio alginolyticus Uncharacterized 11.6 kDa protein in scrR 3'region Proteins 0.000 description 1
- 101000827562 Vibrio alginolyticus Uncharacterized protein in proC 3'region Proteins 0.000 description 1
- 101000778915 Vibrio parahaemolyticus serotype O3:K6 (strain RIMD 2210633) Uncharacterized membrane protein VP2115 Proteins 0.000 description 1
- 102000052547 Wnt-1 Human genes 0.000 description 1
- 108700020987 Wnt-1 Proteins 0.000 description 1
- 210000002593 Y chromosome Anatomy 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 201000011186 acute T cell leukemia Diseases 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000009830 antibody antigen interaction Effects 0.000 description 1
- 230000009833 antibody interaction Effects 0.000 description 1
- 230000014102 antigen processing and presentation of exogenous peptide antigen via MHC class I Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000006472 autoimmune response Effects 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000007435 diagnostic evaluation Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 230000019975 dosage compensation by inactivation of X chromosome Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 210000004265 eukaryotic small ribosome subunit Anatomy 0.000 description 1
- 210000001808 exosome Anatomy 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000009395 genetic defect Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000005090 green fluorescent protein Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 238000013090 high-throughput technology Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 108091008147 housekeeping proteins Proteins 0.000 description 1
- 210000003917 human chromosome Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 210000004020 intracellular membrane Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 101150109249 lacI gene Proteins 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 1
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- 239000005022 packaging material Substances 0.000 description 1
- 239000000123 paper Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- XEBWQGVWTUSTLN-UHFFFAOYSA-M phenylmercury acetate Chemical compound CC(=O)O[Hg]C1=CC=CC=C1 XEBWQGVWTUSTLN-UHFFFAOYSA-M 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920002704 polyhistidine Polymers 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 229920000379 polypropylene carbonate Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002953 preparative HPLC Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 210000001995 reticulocyte Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 108020003113 steroid hormone receptors Proteins 0.000 description 1
- 102000005969 steroid hormone receptors Human genes 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/002—Vectors comprising a special translation-regulating system controllable or inducible
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/10—Vectors comprising a special translation-regulating system regulates levels of translation
- C12N2840/105—Vectors comprising a special translation-regulating system regulates levels of translation enhancing translation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/80—Vectors comprising a special translation-regulating system from vertebrates
- C12N2840/85—Vectors comprising a special translation-regulating system from vertebrates mammalian
Definitions
- This invention relates to self-tumor antigens and methods and compositions to generate immunity in humans against self tumor antigens.
- This invention is more particularly related to eliciting or enhancing immunity against human self tumor antigen encoded by unconventional reading frames with homology to foreign proteins
- Self proteins are proteins that are expressed by both normal cells and cancer cells. (As opposed to mutated proteins that are unique and thus cancer specific.) Self tumor antigens are typically overexpressed by the cancer cells. Certain self proteins, such as HER-2/neu and c-myc, are known to be involved in malignant transformation. See U.S. Patent Publication No. 20020019331 to Cheever.
- the present invention fulfills this need, and further provides other related advantages.
- the inventor screened a human testis cDNA library with sera from three polycythemia vera (PV) patients who responded to IFN- ⁇ and identified a novel antigen, MPD6.
- MPD6 belongs to the group of cryptic antigens without conventional genomic structure and is encoded by a cryptic open reading frame located in the 3′ untranslated region (3′UTR) of myotrophin mRNA.
- 3′UTR 3′ untranslated region
- MPD6 elicits IgG antibody responses in a subset of PV patients, as well as patients with chronic myelogenous leukemia and prostate cancer, suggesting that it is broadly immunogenic.
- the expression of myotrophin-MPD6 transcripts in tumor cells was upregulated in some tumor cells, but only slightly increased in K562 cells in response to IFN- ⁇ treatment.
- This invention is the first demonstration that a novel unconventional self-tumor antigen encoded in the 3′ untranslated region (3′UTR), and translated by internal ribosome entry site can elicit anti-tumor humoral immune responses.
- This discovery has significantly improved the understanding of how host immune system could expand self antigen repertoire and functional significance of secondary open reading frame in mRNAs in expansion of human proteome.
- the MPD6 antigen can elicit anti-tumor IgG antibody responses, potentially T cell responses.
- Expression of this unconventional antigen is upregulated in responses to interferon- ⁇ (IFN- ⁇ ) stimulation; therefore, this antigen can be used for diagnosis, prognosis and immunotherapy for viral infections, inflammation, autoimmune diseases and tumors.
- IFN- ⁇ interferon- ⁇
- the invention was driven by the desire to develop a new unconventional self-tumor antigen broadly immunogenic in patients with polycythemia vera, which is myeloproliferative disease, chronic myelogenous leukemia and prostate cancer, etc.
- This unconventional self-tumor antigen can be used for diagnosis and prognosis, as well as the target for future immunotherapy.
- This invention is also the first report showing that anti-tumor immune responses, elicited by unconventional self-tumor antigen, may lead to tumor remission.
- the inventor discovered that autoimmune diseases associated with interferon- ⁇ therapy may be contributed by unconventional self-tumor antigens. Immune responses to MPD6 unconventional self-tumor antigen can be targeted for the purposes of diagnosis, prognosis and immunotherapy for viral infections, inflammation, autoimmune diseases and tumors.
- the unconventional self-tumor antigen(s) encoded in the 3′ untranslated region and translated by internal ribosome entry site can elicit humoral and T cell immune responses that are useful for diagnosis, prognosis, and therapy for viral infections, inflammation, autoimmune diseases and tumors.
- the MPD6 internal ribosome entry site can be used for construction of bicistronic gene therapy vectors or other eukaryotic expression vectors for gene expression in biomedical research and biotechnological engineering.
- the invention provides that IRES mediates the translation of unconventional antigens and elicits IgG antibody immune responses that are enhanced by IFN- ⁇ .
- Aberrantly expressed and translated antigens (26) tumor antigens were identified by SEREX (9) using sera from three PV patients who underwent IFN- ⁇ -induced remission, which identified the IRES translated unconventional antigen—MPD6.
- SEREX 9 using sera from three PV patients who underwent IFN- ⁇ -induced remission, which identified the IRES translated unconventional antigen—MPD6.
- the enhancement of IRES-mediated translation of MPD6 by IFN- ⁇ is a novel mechanism of IFN- ⁇ enhanced anti-tumor immune responses.
- the invention provides an isolated nucleic acid sequence selected from the group consisting of SEQ ID NO: 1, fragments thereof, variants thereof, and muteins thereof.
- the invention provides an isolated nucleic acid sequence encoding a polypeptide selected from the group consisting of SEQ ID NO: 2, fragments thereof, muteins thereof, and variants thereof.
- the invention provides a nucleic acid comprising a reporter gene operatively linked to an MPD6-IRES region wherein the MPD6-IRES region is responsive to IFN- ⁇ .
- the invention further provides the nucleic acid, further comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO: 1, fragments thereof, variants thereof, and muteins thereof, and, wherein the reporter gene is a luciferase gene.
- the invention further provides the nucleic acid, further comprising a nucleic acid sequence encoding a polypeptide selected from the group consisting of SEQ ID NO: 2, fragments thereof, muteins thereof, and variants thereof, wherein the MPD6-IRES region is responsive to IFN- ⁇ .
- the invention provides a bicistronic reporter vector comprising a first reporter gene; an MPD6-IRES region; a second reporter gene; and wherein the MPD6-IRES region is responsive to IFN- ⁇ .
- the invention provides a host cell comprising the nucleic acid, wherein the MPD6-IRES region is responsive to IFN- ⁇ and further wherein the host cell is a member selected from the group consisting of eukaryotic cells and prokaryotic cells, and further, wherein the MPD6-IRES region is responsive to IFN- ⁇ .
- the invention provides a substantially purified polypeptide selected from the group consisting of SEQ ID NO: 2, fragments thereof, muteins thereof, and variants thereof.
- the invention provides a vaccine for the protection of humans against cancer, comprising: a recombinant vector virus that expresses in vivo a heterologous nucleic acid sequence selected from the group consisting of: SEQ ID NO: 1, a nucleic acid sequence encoding SEQ ID NO: 2, fragments thereof, muteins thereof, and variants thereof, together with a pharmaceutically acceptable carrier.
- the invention provides a vaccine composition comprising an immunogenic peptide selected from the group consisting of SEQ ID NO: 2, fragments thereof, muteins thereof, and variants thereof.
- the invention provides an immunogenic peptide selected from the group consisting of SEQ ID NO: 2, fragments thereof, muteins thereof, and variants thereof.
- the invention provides an isolated nucleic acid encoding an immunogenic peptide selected from the group consisting of SEQ ID NO: 2, fragments thereof, muteins thereof, and variants thereof.
- the invention provides an isolated antibody, wherein said antibody selectively binds a) an MPD6 polypeptide with an amino acid sequence of SEQ ID NO: 2; b) an MPD6 polypeptide that is encoded by a nucleic acid molecule that hybridizes to the nucleic acid sequence of SEQ ID NO: 1 under stringent conditions, comprising 50% formamide, 0.1% bovine serum albumin, 0.1% Ficoll, 0.1% polyvinylpyrrolidone, 50 mM sodium phosphate (pH 6.5), 750 mM NaCl, and 75 mM sodium citrate at 42° C., with washes at 42° C.
- the invention further provides the antibody, wherein the antibody is of polyclonal or monoclonal origin.
- the invention provides a method of eliciting or enhancing an immune response to a human self tumor antigen such as MPD6 (SEQ ID NO: 18), comprising immunizing a human being with an unconventional antigen that is homologous to foreign proteins or foreign peptides but normally not expressed unless stimulated by interferons or cytokines.
- a human self tumor antigen such as MPD6 (SEQ ID NO: 18)
- the invention provides a method of treating or preventing a disorder selected from the group consisting of viral infections, inflammation, autoimmune disease, and cancer comprising administering to said subject a therapeutically effective amount of the vaccine composition according to claim 12 .
- the invention provides a method of identifying a potential therapeutic agent for the treatment of a disorder selected from the group consisting of viral infections, inflammation, autoimmune disease, and cancer which inhibits IFN- ⁇ induced expression of MPD6 comprising the steps of: (a) providing a reporter vector comprising a reporter gene and an MPD6-IRES region, wherein the MPD6-IRES region is responsive to IFN- ⁇ c; (b) providing a test agent; (c) providing IFN- ⁇ ; (d) combining the reporter vector, the test agent, and IFN- ⁇ ; (e) measuring reporter gene activity in the presence of test agent; (f) measuring reporter gene activity in a control sample; and (g) comparing reporter gene activity in the control sample compared to the test sample, to identify a compound which modulates a disorder selected from the group consisting of viral infections, inflammation, autoimmune disease, and cancer, further wherein the reporter vector comprising a reporter gene and the MPD6-IRES region responsive to IFN- ⁇ is in a stably transfected cell
- the invention provides a method of treating a disorder selected from the group consisting of viral infections, inflammation, autoimmune disease, and cancer in a patient in need thereof by administration of an effective amount of a compound which modulates the activity of a member of the group selected from MPD6, the MPD6-IRES region activity, and combinations thereof.
- the invention provides a kit comprising an immunogenic peptide comprising an immunogenic peptide selected from the group consisting of SEQ ID NO: 2, fragments thereof, muteins thereof, and variants thereof.
- the invention provides a method of identifying a potential therapeutic agent which inhibits a disorder selected from the group consisting of viral infections, inflammation, autoimmune disease, and cancer comprising the steps of: (a) providing a cell comprising a reporter gene operatively linked to an MPD6-IRES region; (b) contacting the cell with a test agent in the presence of IFN- ⁇ , wherein a decrement in the expression of the reporter gene in the presence of IFN- ⁇ and the test agent, as compared to the expression of the reporter gene in the presence of IFN- ⁇ and the absence of the test agent, indicates that the test agent is a potential cancer therapeutic.
- the invention provides a method of identifying a potential therapeutic agent which a disorder selected from the group consisting of viral infections, inflammation, autoimmune disease, and cancer comprising the steps of: (a) providing a cell comprising a reporter gene operatively linked to an MPD6-IRES region, and the reporter gene; (b) contacting said cell with a test agent under conditions wherein said cells express the reporter gene, wherein a decrement in the expression of the reporter gene as compared to a control indicates that the test agent is a potential therapeutic for a disorder selected from the group consisting of viral infections, inflammation, autoimmune disease, and cancer, and further, wherein the cell is a member selected from the group consisting of eukaryotic cells, and prokaryotic cells, and further wherein the reporter gene is a luciferase gene.
- the invention provides a diagnostic kit for the detection of MPD6 antigen comprising a container comprising at least one antibody wherein the at the least one antibody specifically binds to an epitope of MPD6, further comprising a solid support, wherein the solid support is selected from the group consisting of wells of reaction trays, test tubes, polystyrene beads, strips, membranes and microparticles.
- the invention further provides the diagnostic kit, further comprising a label, wherein the label is selected from the group consisting of enzymes, radioisotopes, fluorescent compounds and chemiluminescent compounds, and further wherein the enzymatic label is horseradish peroxidase.
- the invention further provides the diagnostic kit further comprising a hapten and labeled anti-hapten system wherein the hapten is conjugated to a labeled murine monoclonal antibody.
- the invention provides a method for detecting the presence of MPD6 peptide in a biological sample comprising a) contacting a biological sample with an anti-MPD6 antibody to form a MPD6-antibody complex; b) contacting the MPD6-antibody complex with a detection antibody so that the detection antibody binds to the soluble MPD6-antibody complex; and c) detecting the presence of the detection antibody that bound to the MPD6-antibody complex, thereby detecting the presence of MPD6 peptide in the sample, and further wherein the biological sample is a member selected from the group consisting of whole blood, serum, plasma, cerebrospinal fluid, saliva, urine, spinal fluid, synovial fluid, amniotic fluid and cranial fluid, and lymphocyte or cell culture supernatants.
- the invention provides a method for monitoring the course of disease in a patient which comprises quantitatively determining in a first cell sample from the subject the presence of MPD6 peptide and comparing the amount so determined with the amount present in a second sample from the subject, such samples being taken at different points in time, a difference in the amounts determined being indicative of the course of disease.
- the invention provides a method for monitoring the course of disease in an cancer patient subject which comprises: obtaining a first sample from the subject; determining from the first sample at least one measure of a MPD6 peptide; at a different time, obtaining a second sample from the subject; determining from the second sample at least one measure of a MPD6 peptide; wherein a difference in the measured MPD6 peptide determined from the first sample and the second sample being indicative of the course of disease.
- the invention provides a method of diagnosing a disease condition related to a disorder selected from the group consisting of viral infections, inflammation, autoimmune disease, and cancer in a patient comprising: obtaining a blood sample from the patient; determining from the sample at least one measure of a MPD6 peptide; presenting such measure; and applying the measure of the MPD6 peptide selectively as a diagnostic evaluation of a disease condition related to a disorder selected from the group consisting of viral infections, inflammation, autoimmune disease, and cancer.
- FIG. 1 Molecular Features of MPD6.
- A Schematic representation of the location of unconventional antigen MPD6 gene in the 3′ untranslated region (3′UTR) of myotrophin mRNA (GenBank accession number: NM — 145808) as well as the genomic structure of the myotrophin-MPD6 gene locus (GenBank accession number: NT — 007933.14).
- the MPD6 open reading frame (ORF) (GenBank accession number: AY611627 (SEQ ID NO: 1)) is located in the region by 3061-3237 in the 3′UTR of myotrophin, while the primary ORF myotrophin is located in the region by 229-585.
- An internal ribosome entry site is also located in the region of the 3′UTR of myotrophin, by 2855-2952 upstream of MPD6 ORF (SEQ ID NO: 18).
- the MPD6 ORF encodes a 58 amino acid protein. (SEQ ID NO: 19).
- the start codon is an unconventional start codon AUU (isoleucine), rather than the conventional start codon AUG (methinione).
- Hydrophilicity plot analysis using by Kyte-Dolittle method indicated that MPD6 has a C-terminal hydrophilic region, which corresponds to the region achieving the higher Jameson-Wolf antigenic index.
- MPD6 peptide used in the ELISA was synthesized according to the MPD6 sequence from aa 39 to aa 58.
- the lanes N1 to N10 indicate various normal tissues in the order of brain (N1), liver (N2), placenta (N3), small intestine (N4), colon (N5), thymus (N6), spleen (N7), prostate (N8), testis (N9), and ovary (N10), respectively.
- the lanes T1 to T 10 indicate various tumor cells in the order of acute T cell leukemia (Jurkat cells) (T1), Burkitt's lymphoma (CA46) (T2), breast cancer (MDA-MD-453) (T3), Burkitt's lymphoma (Namalwa) (T4), epidermial carcinoma (A-431) (T5), uterine carcinoma (MES-SA) (T6), Burkitt's lymphoma (Raji) (T7), osterosarcoma (MG-63) (T8), histiocytic lymphoma (U-937) (T9), and cervical adenocarcinoma (Hela S3) (T10), respectively.
- Jurkat cells Jurkat cells
- T1 Burkitt's lymphoma
- CA46 Burkitt's lymphoma
- MDA-MD-453 breast cancer
- Burkitt's lymphoma Nemalwa
- T4 Burkitt'
- the detection rates of the IgG antibody responses to MPD6 peptide in the group of CML patients treating with IFN-.alpha. are statistically higher than that of CML patients treating with other therapies (the Chi-Square Goodness-of-Fit Test; p ⁇ 0.05, marked with *).
- FIG. 2 The predicted stem-loop structure in MPD6-IRES.
- the cis-acting regulatory elements in 3′ untranslated region (3′UTR) were analyzed using the IRES website at and the UTR website at with generous support by Dr. Sabino Liuni at the Bioinformatics and Genomic Group in Italy.
- the secondary structures of MPD6-IRES (A and D), EMCV-IRES (B and E), and XIAP-IRES (C and F) were predicted by using two web-based algorithms MFOLD-Zuker (A, B, and C), and the RNAfold (D, E, and F).
- the free energy of the secondary structure of these IRES regions were also calculated with both algorithms.
- the start codon and IRES region of MPD6 are indicated.
- FIG. 3 Upregulated translation of EGFP directed by MPD6-IRES in response to Interferon- ⁇ (IFN- ⁇ ) stimulation.
- ORF primary open reading frame
- EGFP as the downstream secondary ORF were constructed (upper left panel), including (1) a complete sequence (myotrophin 3′UTR plus MPD6-IRES) between myotrophin ORF and MPD6 ORF was placed between DsRed ORF and EGFP ORF; (2) a deletion mutant with the 5′ portion of the myotrophin 3′UTR but having no MPD6-IRES region in between DsRed ORF and EGFP ORF; and (3) a bicistronic vector control with EMCV-IRES as an documented IRES positive control.
- the non-transfected cells were used as a negative control for DsRed and EGFP expression (not shown).
- the bivariate plots show the DsRed fluorescence positive cells (ordinate) and the EGFP fluorescence positive cells (abscissa), and percentages of cells in each quadrant in the K562 cells stably-transfected with each bicistronic reporter construct, and stimulated with IFN- ⁇ for 0, 10, and 24 hours. The experiments were repeated three times, the representative results were shown.
- the ratio of the percentage of EGFP positive cells after IFN- ⁇ stimulation over that before IFN- ⁇ stimulation were calculated.
- the ratio of the percentage of EGFP positive cells in MPD6-IRES transfected group 24 hrs after IFN- ⁇ stimulation over that before IFN- ⁇ stimulation was 2.3, which was significantly higher than the upper limit (1.36) of the DsRed confidential intervals (p ⁇ 0.05).
- the upregulation of the expression of eIF-2 ⁇ and phosphorylated eIF-2 ⁇ in responses to IFN- ⁇ stimulation in myeloid leukemia K562 cells was measured by Western blots with specific antibodies to eIF-2 ⁇ and phosphorylated elf-2 ⁇ , respectively, at the time points as indicated.
- the Western blot with antibodies to ⁇ -actin was performed as a house keeping protein control and a no-response control for IFN- ⁇ stimulation.
- the relative densitometric units were calculated by normalizing the densities of the eIF-2 ⁇ and phosphorylated eIF-2 ⁇ with that of ⁇ -actin in the same sample.
- the relative densitometric units for the expression of eIF-2 ⁇ and phosphorylated eIF-2 ⁇ after IFN- ⁇ stimulation over that before IFN- ⁇ stimulation were calculated and shown as the percentages.
- C The MPD6 expression in K562 myeloid leukemia cells stimulated with IFN- ⁇ detected by semi-quantitative RT-PCR. The upregulation of MPD6 transcripts in responses to IFN- ⁇ stimulation in myeloid leukemia K562 cells was measured by semi-quantitative RT-PCR at the time points as indicated (the left panel). The RT-PCR amplification of ⁇ -actin transcripts was performed as a house keeping gene control for RT-PCR and a no-response control for IFN- ⁇ stimulation.
- the RT-PCR amplification of ISG15 was used as a positive control for IFN- ⁇ stimulation.
- the relative densitometric units were calculated by normalizing the densities of the PCR products of MPD6 and ISG15 with that of ⁇ -actin in the same sample.
- the relative densitometric units for the expression of myotrophin/MPD6 and ISG15 transcripts after IFN- ⁇ stimulation over that before IFN- ⁇ stimulation were calculated and shown as the percentages.
- D The proposed working model of MPD6 translation mediated by MPD6-IRES.
- MPD6-IRES is found to be capable in mediation of upregulated translation of MPD6 in response to IFN- ⁇ stimulation, which may result from IFN- ⁇ mediated phosphorylation of eIF-2 ⁇ .
- testis expression cDNA library was screened by SEREX using diluted sera collected from the patients with PV who responded to IFN- ⁇ therapy (2).
- Testis is an immune privileged site where self-antigens are not presented to host immune system (33, 34).
- screening a testis expression cDNA library using SEREX with sera from various tumor patients has proved to be a useful approach to identifying the tumor-associated antigens that are aberrantly expressed in tumors but not normal tissues.
- PV patients were chosen for cDNA library screening based on two criteria: 1.
- the isolated clone (710 by insert) was identical to myotrophin mRNA ( FIG. 1A ).
- Myotrophin interacts with rel/NF-kB (37, 38) and converts NF-kB p50-p65 heterodimers to homodimers (39).
- the coding sequence of the isolated clone was located in the mRNA-sense strand of myotrophin mRNA, however, the coding sequence was in the 3′UTR (bp 3061-3237) of myotrophin mRNA (37) ( FIG. 1A ).
- Exon 4 encodes an mRNA from by 499 to by 3750, which covers the C-terminal 29 amino acids of myotrophin and a 3′UTR that also includes the MPD6 reading frame ( FIG. 1A ).
- MPD6 and myotrophin share the same mRNA transcript that is independent of alternative splicing ( FIG. 1A ). Therefore, MPD6 can not be generated by the following two mechanisms: (1) encoding by a separated exon potentially transcribed by a cryptic promoter as showed for transcription of self-tumor antigen CML66L isoform, CML66S (20); and (2) integration into the C-terminus of myotrophin by exon skipping mechanism (41).
- the MPD6 reading frame had neither a canonical start codon (AUG) nor an optimal Kozak consensus sequence (A/GNNAUGG) (SEQ ID NO: 20; SEQ ID NO: 21) (42).
- this sequence started with the unconventional start codon AUU encoding isoleucine (17, 18), one of the start codons that was previously demonstrated to initiate cryptic antigen peptide translation (19, 43).
- this reading frame matched one (the slip frame) of the three forward fusion frames of the library vector pTriplEx, suggesting that MPD6 sequence fused in the library vector was recognized by antibodies in the sera of patients during SEREX screening.
- MPD6 amino acid sequence showed no significant homologies to any known proteins in the NCBI-GenBank databases and the SEREX database, indicating that it is a novel protein.
- the following features of MPD6 demonstrate that it is a human protein-encoding sequence: (1) the frequencies of amino acid codon usage including those amino acid residues with multiple codons (44) were identical to those used in human proteins; (2) the analysis of protein domains and motifs on the PROSITE database demonstrated that two overlapped regions of MPD6 , including the first one from aa 17 to aa 38, and the second one from aa 24 to aa 45, were identical to the leucine zipper pattern (Leu-x(6)-Leu-x(6)-Leu-x(6)-Leu) (the PROSITE ID#: PS00029) ( FIG.
- MPD6 has the characteristics of short protein-encoding ORFs as previously reported (46).
- Homo sapiens myeloproliferative disease-associated SEREX antigen mRNA was deposited with GenBank, accession number AY611627 (SEQ ID NO: 1).
- novel antigen MPD6 was identified using sera from female patients; however, myotrophin-MPD6 gene loci is located on human autosomal chromosomes 7q33 (80) rather than on the Y chromosome, indicating that anti-tumor immune responses enhanced by IFN- ⁇ therapy in CML but not PV are at least partially mediated by novel self-tumor antigens, rather than Y chromosome-encoded male-specific antigens (80). Correlation of antigen-specific IgG immune responses with the remission in PV and CML patients (3, 81) indicated that immune responses mediated by both unconventional and conventional antigens may contribute to the MPD remission.
- Detection of IgG antibodies to MPD6 in patients with tumors indicates that expression of myotrophin-MPD6 transcripts is upregulated in some tumors. Since MPD6 is always located in the same 3.77 kb transcripts with myotrophin ORF, therefore, the 3.77 kb myotrophin-MPD6 mRNAs detected by Northern blots confirm the authenticity of MPD6.
- the Northern blots examining the expression of MPD6 transcripts in 10 normal tissues are depicted in the upper panel of FIG. 1C . To avoid possible variation in sample preparation and loading, the ratio of the density of MPD6 transcript over the density of ⁇ -actin in the same sample was calculated as relative densitometric unit (32).
- MPD6 has one hydrophilic region and also achieved high antigenic index scores (47), indicating that this region has potential to be a binding epitope for antibody interactions.
- SD standard deviation
- antibody-recognized antigenic epitopes of self-antigens 48 was in the range of 1.56 to 4.36 (21).
- MPD6 antigen epitope was immunogenic in vivo.
- a MPD6 peptide was synthesized using the amino acid sequence of the second antigen epitope of MPD6 from aa 39 to aa 58.
- the ELISA using the MPD6 peptide showed that the MPD6 epitope-specific IgG antibody responses could be detected in 7.7% and 5.7% of PV patients receiving either IFN- ⁇ or other therapies, respectively ( FIG. 1D ).
- MPD6-specific IgG antibody responses could be detected in 15.6% and 5.0% of CML patients receiving either IFN- ⁇ or other therapies, respectively.
- anti-MPD6 IgG antibodies were also found in 23.7% of patients with prostate cancer.
- the mechanism of translation of the cryptic ORF located in the 3′UTR of myotrophin into a protein antigen was determined.
- Potential IRESs located in the upstream of MPD6 promoted the translation of MPD6 were examined and the analysis of the UTR database (27) showed an IRES-containing region located upstream of MPD6, as shown in FIGS. 1A , 2 A, and 2 D. Since some cellular IRESs may contain a common Y-type stem-loop structural motif (50), the sequences upstream of MPD6 were searched for stable stem-loop structures by applying two prediction algorithms for RNA secondary structure, MFOLD (28) and RNAfold (29) for the prediction accuracy higher than that using one algorithm. As shown in FIG.
- the encephalomyocarditis virus (EMCV) IRES region from the widely-used bicistronic expression vector IRES2-EGFP had a stable stem-loop structure with a low free energy; i.e. ⁇ 112.9 kcal/mol (the MFOLD algorithm, FIG. 2B ), or ⁇ 123.34 kcal/mol (RNAfold algorithm, FIG. 2E ).
- the IRES-containing region located upstream of MPD6 has a stable stem loop structure with the free energy of either ⁇ 77.2 kcal/mol calculated by the MFOLD algorithm ( FIG. 2A ) or ⁇ 90.39 kcal/mol calculated by the RNAfold algorithm ( FIG. 2D ).
- EMCV IRES-mediated EGFP expression remained stable from 0 hour (22.60% in FIG. 3 A-3-0 hr) to 24 hours (20.82% in FIG. 3 A-3-24 hr) after IFN- ⁇ stimulation, indicating that the response of IRES-mediated protein translation to IFN- ⁇ stimulation was MPD6-IRES specific.
- EGFP downstream of MPD6-IRES was the secondary ORF in the bicistronic mRNA transcript that did not contain any introns and splicing signals (53). Therefore, the EGFP translation (FIG. 3 A-1) could not be mediated by m7G cap-dependent mechanism or regulated by RNA alternative splicing.
- Phosphorylated eIF-2 ⁇ was upregulated (681.5% at 10 hrs) in response to IFN- ⁇ stimulation, whereas eIF-2 ⁇ was only upregulated in a modest manner (141.2% at 10 hrs) ( FIG. 3B ). Since the unconventional leucine start codon is enhanced in the presence of phosphorylated eIF-2 ⁇ (17), the upregulated phosphorylated eIF-2 ⁇ in response to IFN- ⁇ stimulation (23) might enhance MPD6 translation, which is mediated by the unconventional isoleucine start codon.
- IRES-mediated translation or the transcription of myotrophin-MPD6 is the major mechanism for upregulation of MPD6 after IFN- ⁇ stimulation.
- FIG. 3C as a positive control, the expression of ISG15 RNA transcripts was significantly upregulated (116.8%) in response to IFN- ⁇ stimulation (31), indicating the cells were appropriately stimulated with IFN- ⁇ .
- the transcription of myotrophin-MPD6 mRNA was increased only 16.1% after IFN- ⁇ stimulation.
- the MPD6-IRES mediated translation of EGFP was significantly increased by 130% (FIG. 3 A-1-24 hr and the lower left panel of FIG. 3A ).
- Interferon- ⁇ a pleiotropic cytokine
- IFN- ⁇ Interferon- ⁇
- CML chronic myeloid leukemia
- MPD myeloproliferative disease
- IFN- ⁇ In addition to its direct cytotoxic effects on tumors, IFN- ⁇ has been shown to enhance anti-tumor immune response (1). Cytogenetic response to IFN- ⁇ therapy in CML is often associated with therapy-related autoimmunity (5), indicating that anti-self antigen immune responses induced by IFN- ⁇ will play an important role in controlling these diseases. The mechanism of IFN- ⁇ regulation of the expression of self-antigens (4) remains largely unknown.
- IFN- ⁇ has been shown to enhance anti-tumor immune response (4).
- the self-antigen targets and the mechanism of IFN- ⁇ inducing anti-tumor immune response remain poorly defined.
- the reversion of clonal to polyclonal hematopoiesis in PV patients who responded to IFN- ⁇ therapy has been reported (2).
- These studies have laid a foundation for definition of therapeutic immune responses in patients with PV. Further, current studies indicate that multiple genetic defects may be involved in the pathogenesis of PV (54), reflecting tumor heterogeneity and presumably antigen heterogeneity (55).
- the gain-of-function acquired somatic mutation (V617F) of the tyrosine kinase JAK2 has been identified in most patients with PV and other MPDs (56-60). It remains to be determined if the activating mutation of JAK2 may modulate the expression of tumor antigens and anti-tumor immune responses, a subject currently under investigation (61).
- RNA transcription and processing To determine the novel mechanisms underlying self-antigen immunogenicity, the Inventor focused on RNA transcription and processing.
- the canonical scanning mechanism has been utilized for the translation initiation of more than 90% mRNAs in eukaryotic cells in recruiting ribosomes at the capped 5′ end of mRNAs (24).
- Internal ribosome entry sites IRES are highly structured regions located within the untranslated region that enable ribosomes to initiate translation effectively (24). It is estimated that up to 10% of all mRNAs have the capability to initiate translation by this mechanism (25).
- IRES Internal ribosome entry sites
- SEREX has led to rapid identification of a large number of tumor antigens deposited in the SEREX database. In contrast, a modest number of tumor antigens have been targeted in tumor vaccines and immunotherapies (14).
- Several steps of analysis are Mandatory to evaluate SEREX-defined antigens before they become new target antigens for active immunotherapy, including expression analysis, and serological analysis with sera from tumor patients and normal individuals, etc. (62). As a result, a few tumor antigens have yet be exploited in immunotherapy.
- the Inventor By applying the SEREX technique to screen a human testis expression cDNA library with sera from PV patients, the Inventor identified a novel SEREX antigen that elicits potent humoral immune responses in a subset of patients with MPD.
- the cryptic antigen peptides encoded by introns or UTRs can elicit T cell responses (19, 66), but also demonstrated that unconventional cryptic antigen peptides can elicit IgG antibody responses (23).
- the invention provides a novel cryptic antigen MPD6 and show that its expression is IRES-mediated.
- IFN- ⁇ treatment induces upregulation of numerous genes in tumor cells (69) and other cells (70).
- proteins upregulated by IFN- ⁇ may not necessarily all become self-tumor antigens (14).
- the overexpression of self-antigens must overcome the “threshold” of antigen concentration at which an immune response is initiated as Zinkernagel et al. recently suggested (72, 73).
- overexpressed antigens must access the antigen presentation pathway and immune system by the following mechanisms (74).
- overexpressed antigens may be released from damaged tumor cells due to spontaneous necrosis or apoptosis, and then become available in the extracellular environment for attack by the immune cells, potentially through cross-presentation (75, 76);
- tumor expressed antigens can translocate across the intracellular membranes (77) via binding to heat shock protein 70 and enter the membrane exosome for MHC class II antigen presentation pathway (78).
- some other factors contributing to the immunogenicity of autoantigens and self-tumor antigens have also been proposed (79).
- IRESs internal ribosome entry site
- IRESs are diverse cis-acting RNA sequences which are able to mediate internal entry of the 40S ribosomal subunit directly onto an AUG or other start codons (17) of eukaryotic and viral messenger RNAs (82). IRESs are often found in essential mRNAs encoding regulatory proteins (transcription factors, growth factors, and kinases) (25).
- IRES activity can be modulated in response to mitotic stimuli, hypoxia and other stimuli, p38 MAPK signaling (83), GM-CSF, and IL-3 via the PI3 kinase pathway (84), which indicate that IRES-containing transcripts (85) are important determinants of cellular proliferation and/or differentiation (82).
- IFN- ⁇ hepatitis C virus internal ribosome entry site
- One aspect of the present invention is the polynucleotide sequences essentially as set forth in SEQ ID NO: 1, the complement of these sequences, the RNA versions of both DNA strands and the information otherwise contained within the linear sequence of these polynucleotide sequences, and fragments thereof.
- the polynucleotide encoding MPD6 is exemplified by SEQ ID NO: 1.
- sequences for use with the present invention are those that have greater than about 50 to 60% homology with any portion of the polynucleotide sequences described herein, sequences that have between about 61% and about 70%; sequences that have between about 71 and about 80%; or between about 81% and about 90%; or between 91% and about 99%; or which contain nucleotides that are identical, functionality equivalent, or functionally irrelevant, with respect to the nucleotides present in SEQ ID NO: 1 are considered to be essentially similar. Also encompassed within the present invention are nucleic acids that encode polypeptides that are at least 40% identical or similar to the amino acid sequences shown in SEQ ID NO: 2.
- the invention also encompasses other nucleic acids or nucleic acid like molecules that are sufficient in any regard to mimic, substitute for, or interfere with the MPD6 polynucleotide sequences, as exemplified by SEQ ID NO: 1, or fragments thereof. It will also be understood that the nucleic acid and amino acid sequences may include additional residues, such as additional 5′- or 3′-sequences, and yet still be essentially as set forth in one of the sequences disclosed herein, so long as the sequence meets the criteria set forth, including the maintenance of functionality, or for the purpose of engineering altered functionality with respect to MPD6.
- DNA or RNA segments including oligonucleotides, polynucleotides and fragments thereof, including DNA or RNA or nucleic acid-like sequences of genomic or synthetic origin, single or double stranded.
- the invention includes nucleic acid molecules, or nucleic acid-like molecules that are able to hybridize to the sequences in SEQ ID NO: 1, under stringent or under permissive hybridization conditions, or to the complement of said sequences.
- the invention also includes oligonucleotide, or oligonucleotide-like sequences such as phosphorthioate, or peptide nucleic acid sequences, which possess sufficient similarity with the sequences disclosed herein such that they are able to stably hybridize to the disclosed sequences, or their complements.
- Such sequences may be intended as antisense regulators of gene expression, or for the selective amplification or extension of adjoining sequences, for instance by PCR using a given annealing temperature, as would be determined by someone skilled in the art.
- related sequences in other organisms, or homologs will be readily identified by hybridization using the present sequences.
- Recombinant vectors including for example plasmids, phage, viruses, and other sequences, and isolated DNA or RNA segments may therefore variously include the MPD6 gene sequences or their complements, and coding regions, as well as those that may bear selected alterations or modifications that nevertheless include MPD6 segments or may encode biologically or experimentally relevant amino acid sequences.
- Such sequences may be created by the application of recombinant DNA technology, where changes are engineered based on the consideration of the nucleotides or amino acids being exchanged, deleted, inserted, fused, or otherwise modified.
- One aspect of the invention is the protein, polypeptide, oligopeptide, or amino acid sequences or fragments thereof, of MPD6, essentially as set forth in SEQ ID NO: 2.
- the MPD6 polypeptide is exemplified by SEQ ID NO: 2.
- the invention thus applies to MPD6 polypeptide sequences, or fragments thereof, and nucleic acids which encode such polypeptides, such as those of other species.
- the invention thus encompasses amino acid sequences, or amino acid-like molecules, that are sufficient in any regard to mimic, substitute for, or interfere with the MPD6 amino acid sequences, or fragments thereof.
- the invention encompasses MPD6 amino acid sequences that have been altered in any form, either through the use of recombinant engineering, or through post-translational or chemical modifications, including those that may be produced by natural, biological, artificial, or chemical methods.
- this invention is not limited to the particular amino acid sequences presented herein.
- Altered amino acid sequences include those which have been created by the application of recombinant technology such that specific residues, regions, or domains have been altered, and which may be functionally identical, or which may possess unique biological or experimental properties with regards to function or interactions with natural and artificial ligands.
- modifications may confer longer or shorter half-life, reduced or increased sensitivity to ligands that modify function, ability to detect or purify polypeptides, solubility, and so forth.
- sequences may be shorter oligopeptides that possess an antigenic determinant, or property that interferes, or competes, with the function of a larger polypeptide, and those that affect interactions between MPD6 other proteins, other nucleic acid regions, and other proteins.
- sequences may be created by the application of the nucleotides or amino acids being exchanged, deleted, inserted, fused, or otherwise modified.
- the current invention within, the sequences that may be naturally present as extensions of, or insertions within, the sequences disclosed herein, including alternative or longer N- and C-terminal sequences, or alternatively spliced protein isoforms.
- Production and purification of polypeptides may be achieved in any of a variety of expression systems known to those skilled in the art, including recombinant DNA techniques, genetic recombination, and chemical synthesis.
- expression in prokaryotic cells may be achieved by placing protein coding nucleic sequences downstream of a promoter, such as T7, T3, lacI, lacZ, trp, or other cellular, viral, or artificially modified promoters including those that may be inducible by IPTG, tetracycline, maltose, and so forth.
- a promoter such as T7, T3, lacI, lacZ, trp, or other cellular, viral, or artificially modified promoters including those that may be inducible by IPTG, tetracycline, maltose, and so forth.
- Such promoters are often provided for in commercially available recombinant DNA vectors such as pRSET ABC, pBluescript, pKK223-3, and others, or are easily constructed to achieve such a purpose, and often include the presence of multiple cloning sites (MCS) to facilitate typically contain efficient ribosome binding sites, and in some cases transcription termination signals.
- MCS multiple cloning sites
- Peptides, oligopeptides and polypeptides may also be produced by chemical synthesis, for instance solid phase techniques, either manually or under automated control such as Applied Biosystems 431 peptide synthesizer (Perkin Elmer). After synthesis, such molecules are often further purified by preparative high performance liquid chromatography.
- the invention provides methods for the production of epitopes for antibody production, or the production of small molecules that enhance or interfere with a specific function or interaction of the MPD6 polypeptides.
- Cells for such production are known to include yeast and other fungi, Drosophila and Sf9 cells, cells of other higher eukaryotic organisms such as HeLa, COS, CHO and others, as well as plant cells.
- expression could be achieved in prokaryotic or eukaryotic extracts that are able to translate RNAs into proteins, such as rabbit reticulocyte lysates.
- Prokaryote- and/or eukaryote-based systems can be employed for use with the present invention to produce nucleic acid sequences, or their cognate polypeptides, proteins and peptides. Many such systems are commercially and widely available.
- the insect cell/baculovirus system can produce a high level of protein expression of a heterologous nucleic acid segment, such as described in U.S. Pat. Nos. 5,871,986, 4,879,236, both herein incorporated by reference, and which can be bought, for example, under the name MAXBAC®. 2.0 from INVITROGEN® and BACPACK® BACULOVIRUS EXPRESSION SYSTEM FROM CLONTECH.
- Vectors may be of bacterial origin, which may comprise a promoter of a bacteriophage such as phage or T7 which is capable of functioning in the bacteria.
- the nucleic acid encoding the MPD6 may be transcribed from the vector by T7 RNA polymerase (Studier et al, Methods in Enzymol. 185: 60-89, 1990).
- T7 RNA polymerase In the E. coli BL21 (DE3) host strain, used in conjunction with pET vectors, the T7 RNA polymerase is produced from the 1-lysogen DE3 in the host bacterium, and its expression is under the control of the IPTG inducible lac UV5 promoter. This system has been employed successfully for over-production of many proteins.
- the polymerase gene may be introduced on a lambda phage by infection with an int-phage such as the CE6 phage, which is commercially available (Novagen, Madison, USA).
- Other vectors include vectors containing the lambda PL promoter such as PLEX® (Invitrogen, NL), vectors containing the trc promoters such as pTrcH is Xpress® (Invitrogen), or pTrc99 (Pharmacia Biotech, SE), or vectors containing the tac promoter such as pKK223-3 (Pharmacia Biotech), or PMAL (New England Biolabs, MA, USA).
- cloning also requires the step of transforming a host cell with a recombinant nucleic acid molecule.
- a host cell is “transformed” by a nucleic acid when the nucleic acid is translocated into the cell from the extracellular environment. Any method of transferring a nucleic acid into the cell may be used; the term, unless otherwise indicated herein, does not imply any particular method of delivering a nucleic acid into a cell, nor that any particular cell type is the subject of transfer.
- bacterial host cells such as E.
- coli HB101 can be transformed by electroporation using any commercially-available electroporation apparatus known in the art, such as a GenePulser apparatus (Bio-Rad, Hercules, Calif.).
- mammalian cells such as BHK-21 cells or Vero cells (ATCC CCL-81) are transformed with a recombinant plasmid containing a cloned cDNA by the method of “transfection.”
- the term “transfection” refers to the transfer of genetic material into a eukaryotic cell, such as a mammalian cell, from the external environment of the cell.
- transfection methods of transfection that are available in the art. Such methods include the nucleic acid/CaPO4 co-precipitation method, the diethylaminoethyl (DEAE)-dextran method, the polybrene method, the cationic liposome method (“lipofection”), the electroporation method, the microinjection method, and the microparticle bombardment method.
- DAE diethylaminoethyl
- in vitro transcription is carried out on a recombinant plasmid carrying a cloned cDNA of the invention, under the control of an expressible promoter (i.e., a promoter which is effectively enabled or activated in vitro in the presence of corresponding transcription factors and RNA polymerase).
- an expressible promoter i.e., a promoter which is effectively enabled or activated in vitro in the presence of corresponding transcription factors and RNA polymerase.
- the transcription process generates a fully-infectious mRNA transcript that can be used to transfect (i.e., infect) a cell host, such as BHK-21 (hamster kidney cells) or Vero cells.
- the cDNA is operably linked with the bacteriophage transcriptional promoter, T7; to enable the in vitro transcription of the cDNA using bacteriophage T7 DNA-dependent RNA polymerase.
- T7 bacteriophage transcriptional promoter
- any suitable promoter such as, for example, SP6, T3, any bacterial, viral, phage, or eukaryotic promoter, for controlling the transcription of, for example, the MPD6 gene, or fragment thereof, and for controlling the expression of a nucleotide sequence encoding a reporter is contemplated by the present invention.
- the promoter is typically selected from promoters which are functional in mammalian cells susceptible to infection by the MPD6 gene, or fragment thereof, encoding sequences of the invention, although prokaryotic or phage promoters and promoters functional in other eukaryotic cells may be used.
- the promoter is typically derived from promoter sequences of viral or eukaryotic genes. For example, it may be a promoter derived from the genome of a cell in which expression or transcription of, for example, the MPD6 gene, or fragment thereof, encoding sequence or construct is to occur.
- eukaryotic promoters they may be promoters that function in a ubiquitous manner (such as promoters of ⁇ -actin, ⁇ -actin, tubulin) or, alternatively, a tissue-specific manner (such as promoters of the genes for pyruvate kinase). Tissue-specific or cell-specific promoters specific for lymphocytes, dendritic cells, skin, brain cells and epithelial cells, for example the CD2, CD11c, keratin 14, Wnt-1 and Rhodopsin promoters, respectively.
- the epithelial cell promoter SPC is used. They may also be promoters that respond to specific stimuli, for example promoters that bind steroid hormone receptors.
- Viral promoters may also be used, for example the Moloney murine leukaemia virus long terminal repeat (MMLV LTR) promoter, the rous sarcoma virus (RSV) LTR promoter, the human cytomegalovirus (CMV) IE promoter, or SV40 promoter.
- MMLV LTR Moloney murine leukaemia virus long terminal repeat
- RSV rous sarcoma virus
- CMV human cytomegalovirus
- SV40 promoter SV40 promoter
- the promoters may also be advantageous for the promoters to be inducible so that the levels of expression of, for example, the MPD6 gene, or fragment thereof encoding sequence can be regulated during the life-time of the cell. Inducible means that the levels of expression obtained using the promoter can be regulated.
- any of these promoters may be modified by the addition of further regulatory sequences, for example enhancer sequences.
- Chimeric promoters may also be used comprising sequence elements from two or more different promoters described above. It will be appreciated that the sources of promoter sequences, which typically can be retrieved using recombinant techniques from different cloning vectors and plasmids, etc., can be obtained from commercial sources, such as, NEW ENGLAND BIOLABS, INC. (MA), PROMEGA CORPORATION (WI), or BD BIOSCIENCES (CA), or from the laboratories of academic research groups upon request.
- the invention also relates to cells which contain such recombinant constructs, where the host cell refers to mammalian, plant, yeast, insect, or other eukaryotic cells, or to prokaryotic, or archae, and vectors that are designed for a given host.
- Promoter-vector combinations could be chosen by a person skilled in these arts.
- the desired outcome may not be protein, but RNA, and recombinant vectors would include those with inserts present in either forward or reverse orientations.
- DNA sequences to be expressed as proteins often appear as fusion with unrelated sequences that encode polyhistidine tags, or HA, FLAG, myc and other epitope tags for immunochemical purification and detection, or phosphorylation sites, or protease recognition sites, or additional protein domains such as glutathione S-transferase (GST), maltose binding protein (MBP), and so forth which facilitate purification.
- GST glutathione S-transferase
- MBP maltose binding protein
- Vectors may also be designed which contain elements for polyadenylation, splicing and termination, such that incorporation of naturally occurring genomic DNA sequences that contain introns and exons can be produced and processed, or such that unrelated introns and other regulatory signals require RNA processing prior to production of mature, translatable RNAs.
- Proteins produced in the systems described above could be subject to a variety of post-translational modifications, such as glycosylation, phosphorylation, nonspecific or specific proteolysis or processing.
- MPD6, or variants produced as described above can be achieved by any of several widely available methods.
- Cells may be subject to freeze-thaw cycles or sonication to achieve disruption, or may be fractionated into subcellular components prior to further purification.
- Purification may be achieved by one or more techniques such as precipitation with salts or organic solvents, ion exchange, hydrophobic interaction, HPLC and FPLC chromatographic techniques.
- Affinity chromatographic techniques could include the use of polyclonal or monoclonal antibodies raised against the expressed polypeptide, or antibodies raised against or available for an epitopic tag such as HA or FLAG.
- purification can be aided by affinity chromatography using fusions to the desired proteins such as GSH-affinity resin, maltose affinity resin, carbohydrate (lectin) affinity resin or, in a one embodiment, Ni-affinity resin, and so forth.
- desired proteins such as GSH-affinity resin, maltose affinity resin, carbohydrate (lectin) affinity resin or, in a one embodiment, Ni-affinity resin, and so forth.
- purification is achieved in the presence of denaturing agents such as urea or guanidine, and subsequent dialysis techniques may be required to restore functionality, if desired.
- RNA polymerase any method of in vitro transcription known to one of ordinary skill in the art is contemplated by the instant invention. It will be understood that the method of in vitro transcription of a DNA sequence relies on the operable linkage to an appropriate promoter and that the cognate RNA polymerase is used to direct transcription of the DNA starting at the promoter sequence. It will be further appreciated that the RNA polymerase and promoter can be of bacterial, eukaryotic, or viral (including bacteriophage) origin. Bacteriophage-RNA polymerases are very robust, and the availability of purified recombinant proteins facilitates the generation of large quantities of RNA from cloned cDNA sequences. In contrast, eukaryotic in vitro transcription systems yield relatively small quantities of RNA.
- Bacteriophage-RNA polymerases such as from bacteriophages SP6, T7, and T3, are especially suitable for the generation of RNA from DNA sequences cloned downstream of their specific promoters because, first, their promoters are small and easily incorporated into plasmid vectors and second, the polymerases are quite specific for their cognate promoters, which results in very little incorrect transcriptional initiation from DNA templates.
- Any suitable promoter is contemplated by the instant invention, including, for example, bacterial, phage, viral, and eukaryotic promoters.
- the invention provides a dual luciferase reporter system for measuring recoding efficiencies in vivo or in vitro from a single construct see U.S. Pat. No. 6,143,502 (Grentzmann et al.).
- the firefly luciferase gene fluc
- rluc renilla luciferase gene
- Other reporter genes may also be used, for example, green fluorescent protein, and variants thereof.
- the assay using these reporter plasmids combines rapidity of the reactions with very low background levels and provides a powerful assay.
- In vitro experiments can be performed in 96-well microtiter plates, and in vivo experiments can be performed in 6-well culture dishes. This makes the dual-luciferase assay suitable for high throughput screening approaches.
- the terms “cell,” “cell line,” and “cell culture” may be used interchangeably. All of these term also include their progeny, which is any and all subsequent generations. It is understood that all progeny may not be identical due to deliberate or inadvertent mutations.
- “host cell” refers to a prokaryotic or eukaryotic cell, and it includes any transformable organisms that is capable of replicating a vector and/or expressing a heterologous gene encoded by a vector.
- a host cell can, and has been, used as a recipient for vectors.
- a host cell may be “transfected” or “transformed,” which refers to a process by which exogenous nucleic acid is transferred or introduced into the host cell.
- a transformed cell includes the primary subject cell and its progeny.
- An appropriate host can be determined by one of skill in the art based on the vector backbone and the desired result.
- a plasmid or cosmid for example, can be introduced into a prokaryote host cell for replication of many vectors.
- Bacterial cells used as host cells for vector replication and/or expression include DH5 ⁇ , JM109, and KC8, as well as a number of commercially available bacterial hosts such as SURE®. Competent Cells and SOLOPACK® Gold Cells (STRATAGENE®, La Jolla).
- bacterial cells such as E. coli LE392 could be used as host cells for phage viruses.
- eukaryotic host cells for replication and/or expression of a vector examples include HeLa, NIH3T3, Jurkat, 293, Cos, CHO, Saos, and PC12, etc. Many host cells from various cell types and organisms are available and would be known to one of skill in the art. Similarly, a viral vector may be used in conjunction with either a eukaryotic or prokaryotic host cell, particularly one that is permissive for replication or expression of the vector.
- a diagnostic system in kit form of the present invention includes, in an amount sufficient for at least one assay, a polypeptide, antibody composition or monoclonal antibody composition of the present invention, as a packaged reagent. Instructions for use of the packaged reagent are also typically included.
- a package refers to a solid matrix or material such as glass, plastic, paper, foil and the like capable of holding within fixed limits a polypeptide, antibody composition or monoclonal antibody composition of the present invention.
- a package can be a glass vial used to contain milligram quantities of a contemplated polypeptide or it can be a microtiter plate well to which microgram quantities of a contemplated polypeptide have been operatively affixed, i.e., linked so as to be capable of being immunologically bound by an antibody.
- Instructions for use typically include a tangible expression describing the reagent concentration or at least one assay method parameter such as the relative amounts of reagent and sample to be admixed, maintenance time periods for reagent/sample admixtures, temperature, buffer conditions and the like.
- a diagnostic system of the present invention further includes a label or indicating means capable of signaling the formation of a complex containing a polypeptide or antibody molecule of the present invention.
- a label or indicating means capable of signaling the formation of a complex containing a polypeptide or antibody molecule of the present invention.
- the word “complex” as used herein refers to the product of a specific binding reaction such as an antibody-antigen or receptor-ligand reaction. Exemplary complexes are immunoreaction products.
- label and “indicating means” in their various grammatical forms refer to single atoms and molecules that are either directly or indirectly involved in the production of a detectable signal to indicate the presence of a complex.
- Any label or indicating means can be linked to or incorporated in an expressed protein, polypeptide, or antibody molecule that is part of an antibody or monoclonal antibody composition of the present invention, or used separately, and those atoms or molecules can be used alone or in conjunction with additional reagents such labels are themselves well-known in clinical diagnostic chemistry and constitute a part of this invention only insofar as they are utilized with otherwise novel proteins methods and/or systems.
- the labeling means can be a fluorescent labeling agent that chemically binds to antibodies or antigens without denaturing them to form a fluorochrome (dye) that is a useful immunofluorescent tracer.
- Suitable fluorescent labeling agents are fluorochromes such as fluorescein isocyanate (FIC), fluorescein isothiocyante (FITC), 5-dimethylamine-1-naphthalenesulfonyl chloride (DANSC), tetramethylrhodamine isothiocyanate (TRITC), lissamine, rhodamine 8200 sulphonyl chloride (RB 200 SC) and the like.
- fluorochromes such as fluorescein isocyanate (FIC), fluorescein isothiocyante (FITC), 5-dimethylamine-1-naphthalenesulfonyl chloride (DANSC), tetramethylrhodamine isothiocyanate (TRITC),
- the indicating group' is an enzyme, such as horseradish peroxidase (HRP), glucose oxidase, or the like.
- HRP horseradish peroxidase
- glucose oxidase or the like.
- additional reagents are required to visualize the fact that a receptor-ligand complex (immunoreactant) has formed.
- additional reagents for HRP include hydrogen peroxide and an oxidation dye precursor such as diaminobenzidine.
- An additional reagent useful with glucose oxidase is 2,2′-azino-di-(3-ethyl-benzthiazoline-G-sulfonic acid) (ABTS).
- Radioactive elements are also useful labeling agents and are used illustratively herein.
- An exemplary radiolabeling agent is a radioactive element that produces gamma ray emissions. Elements which themselves emit gamma rays, such as 124 I, 125 I, 128 I, 132 I and 51 Cr represent one class of gamma ray emission-producing radioactive element indicating groups. Particularly preferred is 125 I.
- Another group of useful labeling means are those elements such as 11 C, 18 F, 15 O and 13 N which themselves emit positrons. The positrons so emitted produce gamma rays upon encounters with electrons present in the animal's body. Also useful is a beta emitter, such 111 indium or 3 H.
- labeling of, polypeptides and proteins is well known in the art.
- antibody molecules produced by a hybridoma can be labeled by metabolic incorporation of radioisotope-containing amino acids provided as a component in the culture medium.
- the techniques of protein conjugation or coupling through activated functional groups are particularly applicable. See, for example, Aurameas, et al., Scand. J. Immunol., Vol. 8 Suppl. 7:7-23 (1978), Rodwell et al., Biotech., 3:889-894 (1984), and U.S. Pat. No. 4,493,795, which are all incorporated herein by reference.
- the diagnostic kits of the present invention can be used in an “ELISA” format to detect, for example, the presence or quantity of MPD6 in a body fluid sample such as serum, plasma, or urine, etc.
- ELISA refers to an enzyme-linked immunosorbent assay that employs an antibody or antigen bound to a solid phase and an enzyme-antigen or enzyme-antibody conjugate to detect and quantify the amount of an antigen or antibody present in a sample.
- a description of the ELISA technique is found in Chapter 22 of the 4th Edition of Basic and Clinical Immunology by D. P. Sites et al., published by Lange Medical Publications of Los Altos, Calif. in 1982 and in U.S. Pat. Nos. 3,654,090; 3,850,752; and 4,016,043, which are all incorporated herein by reference.
- a polypeptide, antibody molecule composition or monoclonal antibody molecule composition of the present invention can be affixed to a solid matrix to form a solid support that comprises a package in the subject diagnostic systems.
- the reagent is typically affixed to the solid matrix by adsorption from an aqueous medium although other modes of affixation, well known to those skilled in the art, can be used.
- Useful solid matrices are also well known in the art. Such materials are water insoluble and include cross-linked dextran; agarose; beads of polystyrene beads about 1 micron to about 5 millimeters in diameter; polyvinyl chloride, polystyrene, cross-linked polyacrylamide, nitrocellulose- or nylon-based webs such as sheets, strips or paddles; or tubes, plates or the wells of a microtiter plate such as those made from polystyrene or polyvinylchloride.
- a diagnostic system of the present invention is useful for assaying for the presence of MPD6.
- a system comprises, in kit form, a package containing an antibody to MPD6.
- Another aspect of the invention relates to a method for inducing an immunological response in an individual, particularly a mammal which comprises inoculating the individual with, for example, MPD6, or a fragment or variant thereof. Also provided are methods whereby such immunological response slows bacterial replication.
- Yet another aspect of the invention relates to a method of inducing immunological response in an individual which comprises delivering to such individual a nucleic acid vector to direct expression of, for example, an MPD6, or a fragment or a variant thereof, for expressing, for example, MPD6, or a fragment or a variant thereof in vivo in order to induce an immunological response, such as, to produce antibody and/or T cell immune response, including, for example, cytokine-producing T cells or cytotoxic T cells, to protect said individual from disease, whether that disease is already established within the individual or not.
- an immunological response such as, to produce antibody and/or T cell immune response, including, for example, cytokine-producing T cells or cytotoxic T cells, to protect said individual from disease, whether that disease is already established within the individual or not.
- One way of administering the gene is by accelerating it into the desired cells as a coating on particles or otherwise.
- Such nucleic acid vector may comprise DNA, RNA, a modified nucleic acid, or
- a further aspect of the invention relates to an immunological composition which, when introduced into an individual capable or having induced within it an immunological response, induces an immunological response in such individual to, for example, an MPD6 gene, or protein coded therefrom, wherein the composition comprises, for example, a recombinant MPD6 gene, or protein coded therefrom comprising DNA which codes for and expresses an antigen of said MPD6 or protein coded therefrom.
- the immunological response may be used therapeutically or prophylactically and may take the form of antibody immunity or cellular immunity such as that arising from CTL or CD4+T cells.
- an MPD6 polypeptide or a fragment thereof may be fused with co-protein which may not by itself produce antibodies, but is capable of stabilizing the first protein and producing a fused protein which will have immunogenic and protective properties.
- fused recombinant protein preferably further comprises an antigenic co-protein, such as lipoprotein D from Hemophilus influenzae , Glutathione-S-transferase (GST) or beta-galactosidase, relatively large co-proteins which solubilize the protein and facilitate production and purification thereof.
- the co-protein may act as an adjuvant in the sense of providing a generalized stimulation of the immune system.
- the co-protein may be attached to either the amino or carboxy terminus of the first protein.
- compositions particularly vaccine compositions, and methods comprising the polypeptides or polynucleotides of the invention and immunostimulatory DNA sequences, such as those described in Sato, Y. et al. Science 273: 352 (1996).
- the invention also includes a vaccine formulation which comprises an immunogenic recombinant protein of the invention together with a suitable carrier, the invention also provides that these formulations may be provided in kit form.
- the vaccine may for example, be administered parenterally, including, for example, administration that is subcutaneous, intramuscular, intravenous, or intradermal.
- Formulations suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the bodily fluid, preferably the blood, of the individual; and aqueous and non-aqueous sterile suspensions which may include suspending agents or thickening agents.
- the formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampules and vials and may be stored in a freeze-dried condition requiring only the addition of the sterile liquid carrier immediately prior to use.
- the vaccine formulation may also include adjuvant systems for enhancing the immunogenicity of the formulation, such as oil-in water systems and other systems known in the art. The dosage will depend on the specific activity of the vaccine and can be readily determined by routine experimentation.
- An embodiment of the present invention relates to an antibody that binds to a MPD6 protein.
- a typical amino acid sequence of MPD6 protein is shown in SEQ ID NO: 2. That is, an antibody according to the first embodiment of the present invention is preferably an antibody that specifically binds to, for example, the MPD6 polypeptide.
- Full length MPD6 protein is exemplified in SEQ ID NO: 2, and variants, fragments, muteins, etc., and those proteins derived from this protein. It is known that humans have a diversity of allele mutations and those proteins with one or more amino acids substituted, deleted, inserted, or added are also included in the MPD6 protein. However, it is not limited to these. It is known that humans have a diversity of allele mutations and those proteins with one or more amino acids substituted, deleted, inserted, or added are also included in the MPD6 protein. However, it is not limited to these.
- Fragments of the MPD6 protein may serve as the target antigen for the antibody binding. These antigen fragments may be about 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids in length. The antigen fragments may by about 10, 20, 30, 40, 50, or 100 amino acids in length.
- the antibody of the present invention may be either a polyclonal antibody or a monoclonal antibody. To specifically detect a high molecular weight soluble MPD6 protein, it is desirable to use antibodies to certain limited epitopes and hence monoclonal antibodies are preferable. Molecule species are not particularly limited. Immunoglobulins of any class, subclass or isotype may be used.
- the present invention includes a purified antibody produced in response to immunization with MPD6, as well as compositions comprising this purified antibody.
- Antibodies refer to single chain, two-chain, and multi-chain proteins and glycoproteins belonging to the classes of polyclonal, monoclonal, chimeric, and hetero immunoglobulins; it also includes synthetic and genetically engineered variants of these immunoglobulins.
- “Antibody fragment” includes Fab, Fab′, F(ab′)2, and Fv fragments, as well as any portion of an antibody having specificity toward a desired target epitope or epitopes.
- a humanized antibody is an antibody derived from a non-human antibody, typically murine, that retains or substantially retains the antigen-binding properties of the parent antibody but which is less immunogenic in humans, U.S. Pat. No. 5,530,101, incorporated herein by reference in its entirety.
- An antibody composition of the present invention is typically produced by immunizing a laboratory mammal with an inoculum of the present invention and to thereby induce in the mammal antibody molecules having the appropriate polypeptide immunospecificity.
- the polyclonal antibody molecules are then collected from the mammal and isolated to the extent desired by well known techniques such as, for example, by immunoaffinity chromatography.
- the antibody composition so produced can be used in, inter alia, the diagnostic methods and systems of the present invention to detect MPD6 in a body sample.
- Monoclonal antibody compositions are also contemplated by the present invention.
- a monoclonal antibody composition contains, within detectable limits, only one species of antibody combining site capable of effectively binding MPD6.
- a monoclonal antibody composition of the present invention typically displays a single binding affinity for MPD6 even though it may contain antibodies capable of binding proteins other than MPD6.
- Suitable antibodies in monoclonal form, typically whole antibodies can also be prepared using hybridoma technology described by Niman et al., Proc. Natl. Sci., U.S.A., 80:4949-4953 (1983), which description is incorporated herein by reference.
- a myeloma or other self-perpetuating cell line is fused with lymphocytes obtained from the spleen of a mammal hyperimmunized with a polypeptide of this invention.
- the antibody compositions produced by the above method can be used, for example, in diagnostic and therapeutic modalities wherein formation of an MPD6-containing immunoreaction product is desired.
- measurement of MPD6, or proteins which are immunologically related to MPD6, can be used to detect and/or stage a disease or disorder in a subject.
- the measured amount of the soluble molecule or of the total marker is compared to a baseline level.
- This baseline level can be the amount which is established to be normally present in the body fluid of subjects with various degrees of the disease or disorder.
- An amount present in the body fluid of the subject which is similar to a standard amount, established to be normally present in the body fluid of the subject during a specific stage of the disease or disorder, is indicative of the stage of the disease in the subject.
- the baseline level could also be the level present in the subject prior to the onset of disease or the amount present during remission of disease, or from individuals not afflicted with the disease or condition.
- the present invention also provides for the detection or diagnosis of disease or the monitoring of treatment by measuring the amounts of MPD6 transcript or peptide in a sample before and after treatment, and comparing the two measurements.
- the change in the levels of the markers relative to one another can be an improved prognostic indicator.
- a comparison of the amounts of a total marker with the amount of intra-cytoplasmic marker or membrane-bound marker is also envisioned.
- the present invention provides a method for monitoring the effect of a therapeutic treatment on a subject who has undergone the therapeutic treatment.
- This method comprises measuring at suitable time intervals the amount of a soluble molecule or soluble fragment thereof, or the amount of MPD6 or fragment thereof. Any change or absence of change in the amount of the soluble molecule or in the amount of the MPD6 can be identified and correlated with the effect of the treatment on the subject.
- soluble molecules immunologically related to MPD6 can be measured in the serum of patients by a sandwich enzyme immunoassay (for an example) in order to predict disease prognosis, for example, in viral infections, inflammation, autoimmune diseases, and tumors, or to monitor the effectiveness of treatments such as anti-viral administration.
- Serum samples were obtained from the patients with PV and CML receiving IFN- ⁇ therapy enrolled into Temple University, Baylor College of Medicine, Cornell Medical Center, and M. D. Anderson Cancer Center Institutional Review Board-approved protocols (2). Serum samples from patients with hormone refractory advanced prostate cancer were generously provided by Dr. P. Kantoff from Harvard University (7).
- SSCP single-stranded conformation polymorphism
- the library screening was performed as described previously (6, 23). DNA sequencing was performed by SeqWright (Houston, Tex.).
- RNA sequence analyses were performed using the NCBI-GenBank databases, NCBI-conserved domain databases, and the PROSITE analysis to determine whether cloned sequences were related or identical to genes, proteins, or protein domains in the databases (21).
- the gene organizations such as intron-exon structure and chromosome location, were analyzed by searching in the NCBI-AceView website (21).
- the expression of studied genes was determined by the Northern blots.
- the cis-acting regulatory elements in 3′ untranslated region (3′UTR) were analyzed using the IRES and the UTR websites (27) with generous support of Dr. Sabino Liuni at the Bioinformatics and Genomic Group in Italy.
- the secondary structures of RNAs were predicted by using the MFOLD-Zuker (28) and the Vienna RNA (29) web-based algorithms.
- the MPD6 specific peptide, N-IVQIQHLNIPSSSSTHSSPF-C, (SEQ ID NO:) was synthesized at Sigma-Genosys (Woodlands, Tex.). ELISA was performed as previously described (7).
- the reporter vector DsRed-EMCV-IRES-EGFP (FIG. 3 A-3) was constructed by subcloning DsRed coding sequence (EcoRI-BamHI fragment) into the multiple cloning sites of the commercial bicistronic reporter vector pIRES2-EGFP (Clontech, Palo Alto, Calif.).
- the EcoRI-BamHI DsRed coding fragment was obtained by high-fidelity PCR (Clontech) using the DsRed-EcoRI mRNA sense primer specific for the 5′ end of the DsRed ORF (Table 1) and the DsRed-BamHI antisense primer (Table 1).
- the reporter vector DsRed-3′UTR-MPD6-IRES-EGFP (FIG.
- 3 A-1) was constructed by replacing EMCV-IRES with the 3′UTR-MPD6-IRES (BamHI-BstXI fragment), which was prepared by high-fidelity PCR using the sense primer specific for the 5′ end of the myotrophin 3′UTR (Table 1) and the antisense primer specific for the 3′ end of MPD6-IRES (Table 1).
- the reporter construct DsRed-3′UTR-deleted MPD6-IRES-EGFP (FIG. 3 A-2) was constructed by replacing the EMCV-IRES fragment with the partially deleted 3′UTR-MPD6-IRES fragment in the pIRES2-EGFP vector.
- the deleted 3′UTR-MPD6-IRES fragment was prepared by high-fidelity PCR using the myotrophin 3′UTR mRNA sense primer to pair with the deleted BstXI antisense primer specific for the myotrophin 3′UTR region 600 by upstream of MPD6-IRES (Table 1).
- K562 cells were transfected using the X-tremeGENG Q2 Transfection Reagent (Roche, Diagnostics, Indianapolis, Ind.) with the above-described three bicistronic vectors, respectively.
- Stably transfected cells were selected by the resistance to the neomycin analog G418 (400 ⁇ g/ml; Invitrogen).
- G418 400 ⁇ g/ml; Invitrogen
- transfected K562 cells and mock-transfected K562 control cells were treated with human IFN- ⁇ at a concentration of 1000 ⁇ m' for the time course of 0, 10, and 24 hours.
- the treated K562 cells were then washed with phosphate-buffered saline (PBS) twice.
- PBS phosphate-buffered saline
- the expression of EGFP and DsRed was analyzed on a FACSCalibur flow cytometer (Becton-Dickinson, San Jose, Calif.). Mock-transfected K562 cells were used for negative controls to set up the background gate. Data acquirement and analysis was performed using CellQuest Pro software (Becton-Dickinson).
- EGFP was measured in the FL1 channel (the green fluorescence at 508 nm) and DsRed, in the FL2 channel (the red fluorescence at 583 nm)(30).
- Human IFN- ⁇ (1 ⁇ 105 Units/100 ⁇ ) was purchased from PBL Biomedical Laboratories, (Piscataway, N.J.).
- K562 cells a human myeloid leukemia cell line purchased from American Type Culture Collection ATCC, Manassas, Va.
- RPMI 1640 medium Invitrogen, Carlsbad, Calif.
- the K562 cells were stimulated with 1000 Units/ml of IFN- ⁇ for the time indicated (31).
- RNA preparation, RT-PCR, and PCR cloning were performed as previously described (32).
- a sense primer (PV1ORF5) specific for the 5′ sequence of myotrophin-MPD6 and an antisense primer (PV1ORF3) specific for the 3′ sequence of MPD6 were used for PCR (Table 1).
- the PCR with 25-35 cycles was used for semi-quantitation of MPD6 fragment.
- the 670 by PCR product was cloned into pCR4-TOPO vector (Invitrogen) and confirmed by DNA sequencing.
- the housekeeping gene ⁇ -actin was examined by PCR (sense primer HB-actin5 and anti-sense primer HB-actin3) (Table 1).
- the ethidium bromide staining signals of PCR products were analyzed with a documentation system (Eastman Kodak Company, Rochester, N.Y.) and normalized as relative densitometric units by comparing to ⁇ -actin amplified in the same cDNA preparations (32).
- ISG15 as a positive control for the genes upregulated by IFN- ⁇ stimulation (31), was amplified by PCR with a sense primer ISG5 and an antisense primer ISG3 (Table 1).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/377,444 US8333972B2 (en) | 2006-08-16 | 2007-08-16 | Unconventional antigen translated by a novel internal ribosome entry site elicits antitumor humoral immune reactions |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US82258006P | 2006-08-16 | 2006-08-16 | |
PCT/US2007/076088 WO2008022253A2 (fr) | 2006-08-16 | 2007-08-16 | Antigène non conventionnel traduit par un site interne d'entrée du ribosome innovant qui suscite des réactions immunitaires humorales antitumorales |
US12/377,444 US8333972B2 (en) | 2006-08-16 | 2007-08-16 | Unconventional antigen translated by a novel internal ribosome entry site elicits antitumor humoral immune reactions |
Publications (2)
Publication Number | Publication Date |
---|---|
US20100136036A1 US20100136036A1 (en) | 2010-06-03 |
US8333972B2 true US8333972B2 (en) | 2012-12-18 |
Family
ID=39083134
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/377,444 Expired - Fee Related US8333972B2 (en) | 2006-08-16 | 2007-08-16 | Unconventional antigen translated by a novel internal ribosome entry site elicits antitumor humoral immune reactions |
Country Status (2)
Country | Link |
---|---|
US (1) | US8333972B2 (fr) |
WO (1) | WO2008022253A2 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPR011700A0 (en) | 2000-09-14 | 2000-10-05 | Austin Research Institute, The | Composition comprising immunogenic virus sized particles (VSP) |
AU2017226956A1 (en) * | 2016-03-03 | 2018-10-11 | Institut Gustave Roussy | PTPS-based vaccines against cancer |
CN111534602A (zh) * | 2020-04-22 | 2020-08-14 | 深圳市血液中心(深圳市输血医学研究所) | 一种基于高通量测序分析人类血型基因型的方法及其应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040031072A1 (en) | 1999-05-06 | 2004-02-12 | La Rosa Thomas J. | Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement |
US20050287544A1 (en) | 2003-12-01 | 2005-12-29 | Francois Bertucci | Gene expression profiling of colon cancer with DNA arrays |
-
2007
- 2007-08-16 WO PCT/US2007/076088 patent/WO2008022253A2/fr active Application Filing
- 2007-08-16 US US12/377,444 patent/US8333972B2/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040031072A1 (en) | 1999-05-06 | 2004-02-12 | La Rosa Thomas J. | Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement |
US20050287544A1 (en) | 2003-12-01 | 2005-12-29 | Francois Bertucci | Gene expression profiling of colon cancer with DNA arrays |
Non-Patent Citations (8)
Title |
---|
Certa, U. et al., Expression modes of interferon-alpha inducible genes in sensitive and resistant human melanoma cells stimulated with regular and pegylated interferon-alpha, Gene, Oct. 2, 2003: 315:79-86. |
Greenspan et al. (Nature Biotechnology 7: 936-937, 1999). * |
Hellen, C.U. et al., Internal ribosome entry sites in eukaryotic mRNA molecules, Genes Dev. Jul. 1, 2001; 15(13); 1593-612, Review, No abstract available. |
International Search Report, PCT/US07/76088 dated Aug. 16, 2007. |
Monji, M., et al., Identification of a novel human cancer/testis antigen, KM-HN-1, recognized by cellular and humoral immune responses, Clin. Cancer Res. Sep. 15, 2004:10 (18 Pt. 1): 6047-57. |
Saiz, J.C. et al., Internal initiation of translation efficiency in different heptatis C genotypes isolated from interferon treated patients, Arch Virol. 1999, 144(2): 215-29. |
Xiong, Z. et al., An unconventional antigen translated by a novel internal ribosome entry site elecits antitumor humoral immune reactions, J. Immunol. Oct. 1, 2006; 177(7); 4907-16. |
Yang, et al., CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemia, Proc. Natl. Acad. Sci U.S.A. Jun. 19, 2001; 98(13): 7492-7. |
Also Published As
Publication number | Publication date |
---|---|
US20100136036A1 (en) | 2010-06-03 |
WO2008022253A2 (fr) | 2008-02-21 |
WO2008022253A3 (fr) | 2008-10-30 |
WO2008022253A8 (fr) | 2009-08-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Seliger et al. | Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells | |
TW201736396A (zh) | 轉染 t 細胞和 t 細胞受體用於癌症免疫治療 | |
TW201742873A (zh) | 用於抗癌免疫治療的轉染t細胞及t細胞受體 | |
BR112014024893B1 (pt) | Sequência de ácido nucleico isolada ou purificada que codifica um receptor de antígeno quimérico (car) e seu uso, cars isolados ou purificados, vetores, métodos para destruir células cancerígenas e polinucleotídeo | |
JP2003518364A (ja) | 乳癌、胃癌および前立腺癌関連抗原ならびにそれらの使用 | |
US20110177079A1 (en) | Cancer-testis antigens | |
Watanabe et al. | Identification of immunoglobulin superfamily 11 (IGSF11) as a novel target for cancer immunotherapy of gastrointestinal and hepatocellular carcinomas | |
Castelli et al. | Novel HLA-Cw8-restricted T cell epitopes derived from tyrosinase-related protein-2 and gp100 melanoma antigens | |
Friedman et al. | Molecular and immunological evaluation of the transcription factor SOX-4 as a lung tumor vaccine antigen | |
US8333972B2 (en) | Unconventional antigen translated by a novel internal ribosome entry site elicits antitumor humoral immune reactions | |
US20040235066A1 (en) | Cancer-testis antigens | |
Xiong et al. | An unconventional antigen translated by a novel internal ribosome entry site elicits antitumor humoral immune reactions | |
US20030211521A1 (en) | Breast cancer antigen | |
EP1962891B1 (fr) | Vaccin à adn pour thérapie anticancéreuse | |
Fedoseyeva et al. | CD4+ T cell responses to self-and mutated p53 determinants during tumorigenesis in mice | |
US20110212116A1 (en) | Immunogenic peptides and uses thereof | |
CN114213527B (zh) | 一种t细胞受体及其应用 | |
US9163088B2 (en) | Tumor antigens elicit anti-tumor humoral immune reactions in a subset of patients with polycythemia vera | |
JP2004512809A (ja) | T細胞受容体γ代替リーディングフレームタンパク質、(TARP)およびその用途 | |
US6664232B1 (en) | HLA-A2 restraint tumor antigen peptide originating in SART-1 | |
WO2008027800A2 (fr) | Méthode améliorant l'efficacité de l'immunothérapie antitumorale spécifique d'antigènes | |
US6746867B1 (en) | Mammalian mesoderm induction early response (MIER) gene family | |
BRPI0706784A2 (pt) | antìgeno de cáncer de testìculo ctsp | |
Neighbors et al. | EpCAM-specific vaccine response by modified antigen and chimeric costimulatory molecule in cynomolgus monkeys | |
Elicits | An Unconventional Antigen Translated by |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:YANG, XIAO-FENG;REEL/FRAME:022811/0518 Effective date: 20090421 |
|
AS | Assignment |
Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF Free format text: CONFIRMATORY LICENSE;ASSIGNOR:TEMPLE UNIVERSITY;REEL/FRAME:026712/0736 Effective date: 20110712 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
FEPP | Fee payment procedure |
Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
LAPS | Lapse for failure to pay maintenance fees |
Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20201218 |